Skip to main content

Table 1 Demographic, clinical and histological characteristics of the patient cohort

From: Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

Treatment group
  DMARDs RTX
Number of patients 22 19
Age (years) 43 (30 to 56) 40 (27 to 53)
Sex (female) 22 (100%) 18 (94.7%)
Disease duration (months) 14 (7 to 21) 13 (6 to 20)
Parotid gland enlargement 18 (81.8%) 16 (84.2%)
Cutaneous vasculitis 2 (9.0%) 3 (15.7%)
Pulmonary involvement 1 (4.5%) 1 (5.2%)
Neurological involvement 3 (13.6%) 2 (10.5%)
Renal involvement 0 (0%) 0 (0%)
Autoimmune cytopenia 7 (31.8%) 8 (42.1%)
Myositis 0 (0%) 0 (0%)
Arthritis. 11 (50%) 9 (47.3%)
Lymphadenopathy 15 (68.1%) 17 (89.4%)
ESSDAI 19.8 (6 to 41) 20.3 (6 to 41)
Prednisonea 22 (12.5) 19 (12.5)
DMARDs (HCQ/MTX/CsA) 22 (15/13/8) 0 (0/0/0)
Chisholm and Mason score ≥3 22 19
Focus score 1.8 (1 to 3.3) 1.8 (1 to 3.4)
  1. Data presented as mean (range) or number (%) unless otherwise stated. CsA, cyclosporine; DMARDs, disease-modifying anti-rheumatic drugs; HCQ, hydroxychloroquine; MTX, methotrexate; RTX, rituximab. aData presented as number of patients (mean dose in milligrams).